APR:NSD-Apria, Inc (USD)

COMMON STOCK | Medical Instruments & Supplies | NSD

Last Closing Price

USD 30.81

Change

+1.17 (+3.95)%

Market Cap

USD 1.04B

Volume

0.51M

Average Target Price

USD 29.50 (-4.25%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Apria, Inc. provides integrated home healthcare equipment and related services in the United States. The company offers home respiratory therapies, including the supply of stationary and portable home oxygen equipment, and non-invasive ventilators; obstructive sleep apnea therapy devices comprising continuous positive airway pressure and bi-level positive airway pressure devices, and patient support services; and negative pressure wound therapy products. It also provides a range of home medical equipment and other products, and services for patients with home care needs; and clinical and administrative support services, and related products and supplies to patients. The company was incorporated in 2018 and is headquartered in Indianapolis, Indiana.

Company Website : http://www.apria.com

Address : 7353 Company Drive, Indianapolis, IN, United States, 46237

Employees : 6,120

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : -0.47

52 Week High : 32.75

Short Ratio : 2.49

52 Week Low : 20.07

Shorted Shares : 628,514

200 Day Moving Average : 23.39

Shorted Shares Previous Month : 493,549

50 Day Moving Average : 23.44

Shares Held By Insiders : 35.68%

Short Percentage : 2.00%

Shares Held by Institutions : 95.3%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-04-09 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ISRG Intuitive Surgical, Inc

+14.13 (+1.83%)

 USD91.19B 87.34 62.84
HOLX Hologic, Inc

+0.05 (+0.07%)

 USD18.96B 13.98 9.48
XRAY DENTSPLY SIRONA Inc

+0.05 (+0.08%)

 USD14.01B 126.19 49.42
NVCR NovoCure Limited

-0.43 (-0.32%)

 USD13.58B 736.94 332.09
MASI Masimo Corporation

-3.12 (-1.31%)

 USD13.11B 57.32 42.63
RGEN Repligen Corporation

+1.94 (+0.95%)

 USD11.18B 183.93 107.05
STAA STAAR Surgical Company

+0.97 (+0.84%)

 USD5.35B 958.17 484.90
ICUI ICU Medical, Inc

+0.18 (+0.09%)

 USD4.32B 50.75 20.53
IRTC iRhythm Technologies, Inc

-1.66 (-1.23%)

 USD3.92B N/A N/A
MMSI Merit Medical Systems, Inc

+0.94 (+1.55%)

 USD3.40B 379.20 35.89

ETFs Containing APR

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Instruments & Supplies)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 1.04B 56% F 63% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Instruments & Supplies)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 61.34 46% F 20% F
Price/Book Ratio N/A N/A N/A N/A N/A
Price / Cash Flow Ratio 5.28 63% D 50% F
EV/EBITDA 7.33 96% A 80% B-
Management Effectiveness  
Return on Equity 85.31% 100% A+ 100% A+
Return on Invested Capital 15.91% 91% A- 88% B+
Return on Assets 9.77% 91% A- 94% A
Debt to Equity Ratio -1,428.69% 100% A+ 99% A+
Technical Ratios  
Short Ratio 2.49 72% C- 45% F
Short Percent 5.71% 34% F 35% F
Beta -0.47 100% A+ 98% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector